Trial Profile
Attention Deficit Hyperactivity Disorder (ADHD) Prediction of Treatment Response
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Sep 2022
Price :
$35
*
At a glance
- Drugs Methylphenidate (Primary) ; Mixed amfetamine salts (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- 22 Sep 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 22 Sep 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2023.
- 30 Aug 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.